Leukocytoclastic Vasulitis Induced by Gefitinib / 대한피부과학회지
Korean Journal of Dermatology
; : 50-52, 2011.
Article
in Ko
| WPRIM
| ID: wpr-171986
Responsible library:
WPRO
ABSTRACT
Gefitinib (Iressa(R), AstraZeneca) is an oral form of an anticancer drug called epidermal growth factor receptor-tyrosine kinase inhibitor. It is widely used for various solid cancers, including lung cancer. Cutaneous adverse reactions induced by gefitinib have recently been reported with an incidence ranging from 49% to 100%, and they include acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail change and disorders of the mucous membranes, eyes and hair. To the best of our knowledge, no cases of leukocytoclastic vasculitis associated with gefitinib have ever been published in the Korean medical literature, and there have been only four such reported cases in other countries. Herein, we report on a case of leukocytoclastic vasulitis induced by gefitinib in a patient with lung cancer.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Phosphotransferases
/
Pruritus
/
Quinazolines
/
Skin
/
Vasculitis
/
Incidence
/
Hyperpigmentation
/
Vasculitis, Leukocytoclastic, Cutaneous
/
Epidermal Growth Factor
/
Exanthema
Type of study:
Incidence_studies
/
Prognostic_studies
Limits:
Humans
Language:
Ko
Journal:
Korean Journal of Dermatology
Year:
2011
Type:
Article